. 2020 Jun 12;20:548. doi: 10.1186/s12885-020-07047-1

Table 1.

Patient eligibility—inclusion and exclusion criteria

Inclusion criteria	Exclusion criteria
1) Age ≥ 20 years 2) Informed consent 3) Histological diagnosis of primary gastric or oesophagogastric junction adenocarcinoma 4) Unresectable gastric or oesophagogastric junction cancer, recurrent gastric, or oesophagogastric junction cancer 5) At least one of i) to iv) listed below, which indicates peritoneal dissemination i) Contrast enema/enterography: obvious malignant intestinal stenosis or deformation of the intestinal wall ii) CT: obvious peritoneal mass or ascites, hydronephrosis not attributable to a cause other than peritoneal dissemination, increased density of peritoneal adipose tissue, thickening of the intestinal wall iii) Clinical signs: palpable metastasis in the pouch of Douglas, board-like rigidity of the abdomen not attributable to a cause other than peritoneal dissemination iv) Operative findings (including exploratory laparoscopy): lesions suggestive of peritoneal dissemination, confirmed by pathological diagnosis of peritoneal dissemination 6) Patients without massive pleural effusion 7) Patients without advanced central nervous system (CNS) metastases 8) Patients with evaluable lesions (whether or not lesions are measurable is irrelevant) 9) Intolerant or refractory to first-line therapy, including fluoropyrimidine 10) Patient without history of using taxane or angiogenesis inhibitors 11) Patients without history of radiotherapy including irradiation of the abdominal region 12) ECOG performance status: 0, 1, or 2 13) Adequate organ function	1) Active multiple cancer (synchronous multiple cancer or metachronous multiple cancer where patient has been disease-free for less than 3 years); however, lesions corresponding to carcinoma in situ (intraepithelial carcinoma) or intramucosal cancer assessed as cured by local treatment are not classified as active multiple cancers. 2) History of sensitivity to any of the drugs used in this study (including alcohol or albumin sensitivity) 3) Patients with a history of surgery under general anaesthesia within 28 days 4) Patients who have had deep vein thrombosis, pulmonary embolism, or another major form of thromboembolism up to 12 weeks prior to enrolment 5) Palliative ascites aspiration (excluding diagnostic puncture for laboratory tests) within the past 2 weeks 6) Active infection requiring systemic treatment 7) Uncontrolled hypertension despite hypotensive drug therapy 8) Diabetes under treatment with continuous insulin use or uncontrolled diabetes 9) Patients with severe pulmonary disease 10) Unstable angina (attacks occurring or exacerbated within the past 3 weeks) or myocardial infarction within the past 3 months 11) Serious haemorrhagic disorder or vasculitis or an episode of serious gastrointestinal bleeding 12) Grade 2 or worse peripheral sensory neuropathy 13) Patients with liver cirrhosis (Child Pugh B or C) or previous hepatic encephalopathy 14) Patients with intestinal obstruction 15) Patients receiving continuous systemic administration of steroids 16) Patients receiving antiplatelet drugs 17) Mental illness or mental symptoms that would interfere with participation in the study 18) Pregnant, breast-feeding, a chance of pregnancy, or expecting to give birth 19) Patients deemed unsuitable as study subjects by an investigator for any other reason

Inclusion criteria

Exclusion criteria

1) Age ≥ 20 years

2) Informed consent

3) Histological diagnosis of primary gastric or oesophagogastric junction adenocarcinoma

4) Unresectable gastric or oesophagogastric junction cancer, recurrent gastric, or oesophagogastric junction cancer

5) At least one of i) to iv) listed below, which indicates peritoneal dissemination

i) Contrast enema/enterography: obvious malignant intestinal stenosis or deformation of the intestinal wall

ii) CT: obvious peritoneal mass or ascites, hydronephrosis not attributable to a cause other than peritoneal dissemination, increased density of peritoneal adipose tissue, thickening of the intestinal wall

iii) Clinical signs: palpable metastasis in the pouch of Douglas, board-like rigidity of the abdomen not attributable to a cause other than peritoneal dissemination

iv) Operative findings (including exploratory laparoscopy): lesions suggestive of peritoneal dissemination, confirmed by pathological diagnosis of peritoneal dissemination

6) Patients without massive pleural effusion

7) Patients without advanced central nervous system (CNS) metastases

8) Patients with evaluable lesions (whether or not lesions are measurable is irrelevant)

9) Intolerant or refractory to first-line therapy, including fluoropyrimidine

10) Patient without history of using taxane or angiogenesis inhibitors

11) Patients without history of radiotherapy including irradiation of the abdominal region

12) ECOG performance status: 0, 1, or 2

13) Adequate organ function

1) Active multiple cancer (synchronous multiple cancer or metachronous multiple cancer where patient has been disease-free for less than 3 years); however, lesions corresponding to carcinoma in situ (intraepithelial carcinoma) or intramucosal cancer assessed as cured by local treatment are not classified as active multiple cancers.

2) History of sensitivity to any of the drugs used in this study (including alcohol or albumin sensitivity)

3) Patients with a history of surgery under general anaesthesia within 28 days

4) Patients who have had deep vein thrombosis, pulmonary embolism, or another major form of thromboembolism up to 12 weeks prior to enrolment

5) Palliative ascites aspiration (excluding diagnostic puncture for laboratory tests) within the past 2 weeks

6) Active infection requiring systemic treatment

7) Uncontrolled hypertension despite hypotensive drug therapy

8) Diabetes under treatment with continuous insulin use or uncontrolled diabetes

9) Patients with severe pulmonary disease

10) Unstable angina (attacks occurring or exacerbated within the past 3 weeks) or myocardial infarction within the past 3 months

11) Serious haemorrhagic disorder or vasculitis or an episode of serious gastrointestinal bleeding

12) Grade 2 or worse peripheral sensory neuropathy

13) Patients with liver cirrhosis (Child Pugh B or C) or previous hepatic encephalopathy

14) Patients with intestinal obstruction

15) Patients receiving continuous systemic administration of steroids

16) Patients receiving antiplatelet drugs

17) Mental illness or mental symptoms that would interfere with participation in the study

18) Pregnant, breast-feeding, a chance of pregnancy, or expecting to give birth

19) Patients deemed unsuitable as study subjects by an investigator for any other reason